Shineco, Inc Subsidiary, Granted USPTO Patent and FDA Marketing Approval for Its In-situ Fecal Specimen Sampling Device
07 Diciembre 2022 - 8:00AM
Shineco, Inc.(“Shineco” or the “Company”; NASDAQ: SISI), a producer
and distributor of Chinese herbal medicines, organic agricultural
and other biotech products, announced that its controlling
affiliate, Changzhou Biowin Pharmaceutical Co., Ltd. (“CBP”), has
been granted a patent (US 11,458,476 B2) by the United States
Patent and Trademark Office (“USPTO”) protecting its in-situ fecal
specimen sampling device for the use of stool test sample
collection, and the marketing approval of the product by the Food
and Drug Administration (“FDA”). This product provides a
massager-like fingertip swab, a collection tube and a lid with
unidirectional sampling inlet. It is a leading stool sample
collection device on the market that can be used for
self-collection while defecation and does not need a container or
plastic bag for this process. After collection, the laboratory
staff can finish all of the testing procedures without opening the
sample tube.
Just a few days ago, this product was presented
at MEDICA 2022 in Düsseldorf, Germany, one of the largest annual
exhibitions of medical devices in the world. Its humane,
convenient, painless and innovative design has attracted the
attention of professionals and potential distributors in the
field.
“We are extremely pleased with the grant of a
U.S. patent and the marketing approval from FDA for our Easy-to-Use
disposable stool test sample collector, which gives us strong
support to optimize the stool sample collection in clinical stool
test,” said Dr. Marvin Liu, the Chairman of CBP, in a press
release, and he also commented, “The stool test is a very common
clinical lab examination and requires the collection of stool
sample from the patient, but the current collection method is not
very convenient and requires the passing of a stool specimen into a
clean, dry container directly or placing a plastic bag inside the
bowl using a toilet. This Easy-to-Use disposable stool test sample
collector provides a very simple, easy and complete privacy
protected tool for stool sample collection. The collection
procedure can be done while defecation on squatting or sitting or
can be done after defecation. This not only prevents samples from
contamination, but also provides a sanitary measure for laboratory
staff to work on the stool sample.”
About
Shineco, Inc.
Incorporated in Delaware in August 1997 and
headquartered in Beijing, China, Shineco is a holding company.
Utilizing modern engineering technologies and biotechnologies,
Shineco produces, among other products, Chinese herbal medicines,
organic agricultural produce, and specialized textiles. For more
information about Shineco, please visit www.biosisi.com.
Forward-Looking Statements
This news release contains “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. These forward-looking statements can be
identified by terminology such as “may”, “will”, “should”, “could”,
“intend”, “expect”, “plan”, “budget”, “forecast”, “anticipate”,
“believe”, “estimate”, “predict”, “potential”, “continue”,
“evaluating” or similar words. Forward-looking statements should
not be relied upon because they are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Examples of forward-looking statements include, among
others, statements we make regarding the benefits of our in-situ
fecal specimen sampling device and our expectation to optimize the
stool sample collection in clinical stool test. You are cautioned
not to rely on any forward-looking statements. Actual results may
differ materially from historical results or those indicated by the
forward-looking statements as a result of a variety of factors
including, but not limited to, risks and uncertainties associated
with the Company’s ability to raise additional funding, its ability
to maintain and grow its business, variability of operating
results, its ability to maintain and enhance its brand, its
development and introduction of new products and services, the
successful integration of acquired companies, technologies and
assets into its portfolio of products and services, marketing and
other business development initiatives, competition in the
industry, general government regulations, economic conditions, the
impact of the COVID-19 pandemic, dependence on key personnel, the
ability to attract, hire and retain personnel who possess the
technical skills and experience necessary to meet the requirements
of its clients, and its ability to protect its intellectual
property. Shineco encourages you to review other factors that may
affect its future results in its registration statements and in its
other filings with the Securities and Exchange Commission. The
forward-looking statements in this press release are based only on
information currently available to us and speak only as of the date
of this press release, and Shineco assumes no obligation to update
any forward-looking statements except as required by the applicable
rules and regulations.
For more information, please
contact:Tina XiaoAscent Investor Relations LLCPhone:
+1-917-609-0333Email: tina.xiao@ascent-ir.com
Shineco (NASDAQ:SISI)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Shineco (NASDAQ:SISI)
Gráfica de Acción Histórica
De May 2023 a May 2024